Introduction Peptide therapeutics are increasingly explored to treat challenging diseases, but immunogenicity risks limit their clinical success. In silico tools enable immunogenicity screening through prediction of peptide-MHCII binding, yet current methods do not account for chemical properties of non-natural amino a...
M. Cairoli, Morten Nielsen, Catherine J. Betts et al.· Frontiers in Immunology· 0 citations
Public repositories of T cell receptor (TCR)-peptide-MHC (pMHC) interactions constitute a critical resource for studying adaptive immunity and developing predictive models of TCR specificity. However, recent evidence suggests that a substantial fraction of reported TCR-pMHC interactions may be incorrectly annotated, li...
J. Lund, S. Deleuran, Morten Nielsen· bioRxiv· 0 citations
It is shown that combining structural modeling with label denoising substantially improves TCR-pMHC specificity prediction, making such approaches an attractive complement to current sequence-based approaches for refining TCR target selection.
Pilar Ballesteros-Cuartero, J. Lund, Morten Nielsen· bioRxiv· 1 citation· ⚡1
CEDAR’s current capabilities, report on progress in curation, database development, and tool availability, and outline the opportunities and challenges ahead for expanding its scope and utility to the cancer research community are described.
Zeynep Koşaloğlu-Yalçın, Ibel Carri, Daniel Marrama et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.